How to avoid future Vioxx-type scandals.
The market withdrawal of rofecoxib (Vioxx) in September 2004 was the logical, if long-overdue, result of what has become a major scandal. How can similar situations be avoided in the future? The authorities must of course come to grips with their responsibilities, but caregivers, patients and journalists also have a role to play. This was the theme of the press conference held at Prescrire headquarters after the annual awards ceremony on 20 January 2005
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002986:Clinical Trials as Topic; D016265:Conflict of Interest; D030881:Disclosure; D017277:Drug Approval; D004345:Drug Industry; D005602:France; D033161:Government Regulation; D006801:Humans; D020452:Journalism; D007783:Lactones / Q000009:adverse effects*; D010003:Osteoarthritis / Q000188:drug therapy; D011358:Product Surveillance, Postmarketing; D013450:Sulfones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D007783:Lactones; D013450:Sulfones